CN104447674A - Compound used as antitumor drug and food - Google Patents
Compound used as antitumor drug and food Download PDFInfo
- Publication number
- CN104447674A CN104447674A CN201410707859.6A CN201410707859A CN104447674A CN 104447674 A CN104447674 A CN 104447674A CN 201410707859 A CN201410707859 A CN 201410707859A CN 104447674 A CN104447674 A CN 104447674A
- Authority
- CN
- China
- Prior art keywords
- novel cpd
- agent
- food
- tea
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013305 food Nutrition 0.000 title claims abstract description 13
- 150000001875 compounds Chemical class 0.000 title claims abstract description 11
- 239000002246 antineoplastic agent Substances 0.000 title abstract description 15
- 229940041181 antineoplastic drug Drugs 0.000 title abstract description 3
- 239000000203 mixture Substances 0.000 claims description 10
- 230000000118 anti-neoplastic effect Effects 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 22
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical class CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 19
- 239000002904 solvent Substances 0.000 description 17
- 238000000034 method Methods 0.000 description 15
- 241000196324 Embryophyta Species 0.000 description 13
- 244000269722 Thea sinensis Species 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- 229940034982 antineoplastic agent Drugs 0.000 description 12
- 235000013616 tea Nutrition 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 11
- 238000000605 extraction Methods 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- -1 furans naphthoquinone Chemical class 0.000 description 9
- 239000002994 raw material Substances 0.000 description 9
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 238000004440 column chromatography Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000003327 cancerostatic effect Effects 0.000 description 4
- 239000001569 carbon dioxide Substances 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000000287 crude extract Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 229930192627 Naphthoquinone Natural products 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000000976 ink Substances 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002953 preparative HPLC Methods 0.000 description 3
- 238000007639 printing Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 229960001866 silicon dioxide Drugs 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- QGZCUOLOTMJILH-UHFFFAOYSA-N 2h-tetrazol-2-ium;bromide Chemical compound [Br-].C1=N[NH+]=NN1 QGZCUOLOTMJILH-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 235000006468 Thea sinensis Nutrition 0.000 description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 150000002791 naphthoquinones Chemical class 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000011403 purification operation Methods 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 241000208688 Eucommia Species 0.000 description 1
- 206010018687 Granulocytopenia Diseases 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 241001048891 Jatropha curcas Species 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 240000002396 Rhinacanthus nasutus Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000003570 biosynthesizing effect Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 235000021329 brown rice Nutrition 0.000 description 1
- ZFXVRMSLJDYJCH-UHFFFAOYSA-N calcium magnesium Chemical compound [Mg].[Ca] ZFXVRMSLJDYJCH-UHFFFAOYSA-N 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 235000012459 muffins Nutrition 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- FUESFIVIIFEDFI-UHFFFAOYSA-N octadecylsilicon Chemical compound CCCCCCCCCCCCCCCCCC[Si] FUESFIVIIFEDFI-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000020333 oolong tea Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 235000020245 plant milk Nutrition 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/16—Eight-membered rings
- C07D313/20—Eight-membered rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The intention provides a compound used as an antitumor drug or tumor prevention and heath care food. The structural formula is shown in the specification.
Description
Technical field
The present invention relates to novel cpd, antineoplastic agent and there are the pharmaceuticals of antitumor action, food or makeup.
Background technology
Antineoplastic agent carcinostatic agent carcinostatic agent is select optionally to act on tumour cell and the preparation less to normal cytotoxicity substantially, but also have the problem on a lot of use to be resolved not yet, the appearance of the fatal side effects such as the leukopenia such as caused by bone marrow depression, thrombopenia, Neutrophilic granulocytopenia, the appearance of the side effect of the Digestive tract obstacles such as nausea and vomiting, and the appearance of the side effect such as alopecia, drug-fast appearance, and because the medicament being difficult to oral administration, route of administration is restricted.Therefore, expect to develop and optionally act on tumour cell and, route of administration few to normal cytotoxicity limits few antineoplastic agent carcinostatic agent carcinostatic agent.
As the antineoplastic agent obtained from natural goods, there will be a known a large amount of compounds, such as, have the report that ametycin, camptothecine, triterpenoid etc. are a large amount of.In addition, as the antineoplastic agent taking natural goods as lead compound, there will be a known D51-7059, Taxane derivative etc.The content of the antineoplastic agent of naphthoquinones system that is relevant to this compound or that be correlated with the biosynthesizing system of this compound, decomposing solution as phone predicts, has about from the extract of Jatropha curcas seed A of manioca grass (Rhinacanthus nasutus (L.) Kurz), the report of B, C, D, G, H, I, K, M, N, Q.In addition, as the synthetic compound relevant to naphthoquinones system antineoplastic agent, there will be a known the antineoplastic agent relevant to furans naphthoquinone derivatives.
Summary of the invention
Novel cpd of the present invention, can be obtained manioca by extraction purification operation as raw material, also can obtain in other plant materials.In addition, also can use by synthesizing the novel cpd obtained.But also manioca can be used, from containing extracting the extract obtained, thick purified or the dry thing of plant materials, the slurry of plant materials other plant materials of novel cpd.
From the plant materialss such as manioca during extraction purification novel cpd of the present invention, any extraction purification operation of usual industrial use can be used.After as the leaf, stem, root, flower etc. of raw material, the phase gathers in due course, directly or implement the drying process of usual air seasoning etc., extraction raw material is made.
That is: by after raw material pulverizing or chopping, extract with solvent, as Extraction solvent, can by water, the alcohols such as ethanol, methyl alcohol, Virahol, the ketone such as acetone, methyl ethyl ketone, the ester such as methyl acetate, ethyl acetate class, the oil loving solvent such as hexane, chloroform is used alone or is formed mixed solvent and uses.Extracting temperature is generally 0 ~ 100 DEG C, is preferably 5 ~ 50 DEG C.Extraction time is 1 hour ~ about 10 days, and quantity of solvent is that on average every part of dried feed is generally 1 ~ 30 times of weight, is preferably 5 ~ 10 times of weight.Extraction operation, by stirring, is also undertaken by dipping placement.Extraction operation repeatedly can carry out 2 ~ 3 times.By filtering or centrifugation and removing in the extracting solution after insoluble sludge or the method for each novel cpd of purifying from the squeezeding juice of plant from the crude extract obtained with aforesaid operations, as long as known crude drug separation purification method, any method can be adopted, but be preferably used alone or in combination two-phase solvent apportion design, counter-current distribution method, column chromatography, preparative high performance liquid chromatography etc.Such as two-phase solvent apportion design, can exemplify by distributing in normal hexane, chloroform, methyl ethyl ketone, ethyl acetate, methyl acetate equal solvent and water, thus target compound is recovered to the method etc. in solvent phase from said extracted liquid.As column chromatography, ion exchange column chromatography method, use positive or the reverse phase silica gel modification dextrane gel as the method for carrier, the Adsorption column chro-matography using DIAION HP-20 etc., use SephadexLH-20 etc. can be exemplified as the gel filtration method etc. of carrier, these methods can be used alone or in combination or use repeatedly.As preparative high performance liquid chromatography, the method for the reversed-phase column using octadecyl silicon etc. can be exemplified, use the method etc. of the normal phase column of silica gel etc.
As the route of administration of antineoplastic agent of the present invention, be not particularly limited, such as, can exemplify administration in the intestines such as oral administration drop rectum with drug, the mucosa delivery of nose administration etc., the drug administration by injection etc. of intravenous administration subcutaneous administration etc.As the formulation of antineoplastic agent of the present invention, form that is any and the matched preparation of medication can be taked, such as can exemplify tablet, powder, granula subtilis, granule, capsule, powder, pill, containing solid preparations such as tablets, the liquid preparations such as solution, suspension, emulsion, syrup, injection, gel preparation etc.Can by directly administrations such as the sterling of each novel cpd, purified, thick purifieds, also can with the excipient pharmacologically allowed together administration.As excipient, as long as monose, disaccharides, polyose, inorganic salts, grease, distilled water etc. are as the usual spendable excipient of preparation, any excipient can be used.When carrying out formulation, also can use the additives such as tackiness agent, lubricant, dispersion agent, suspension agent, emulsifying agent, thinner, buffer reagent, antioxidant, bacterial inhibitor.
Effective dosage of each novel cpd, different according to the difference at the symptom of route of administration, formulation, disease, the age of object etc., be generally and be 0.1 ~ 1000mg, be preferably 0.5 ~ 300mg, more preferably 1 ~ 100mg every day for each person.The content of each novel cpd in oral antineoplastic agent of the present invention, can set and the active constituent content in the optimal preparation of each administration form according to the data of the effective dosage of the form of preparation as the dosage of preparation.
As the form of food, form manioca and the dry thing of plant materials containing each novel cpd being made tea can be exemplified, or be combined with the food etc. of the sterling of each novel cpd, the partial purification product of this novel cpd, the crude extract from containing this novel cpd extracted the plant of this novel cpd, the plant materials slurry containing this novel cpd, the dry thing of the plant materials containing this novel cpd.
As tea, can separately or used in combination with other tea raw materials.As other tea raw material, as long as green tea, oolong tea, Leaf of Assam Tea, black tea, simmer tea, brown rice tea, Eucommia Tea, persimmon-leaf tea, mulberry tea etc. usually used as the edible raw material of tea, any tea raw material can be used.
When obtaining plant milk extract, as long as by hot water extraction, by spendable method in ethanol, aqueous ethanol extraction etc. usually food extraction, any method can be used.From plant materials, crude extract, the partial purification product of each novel cpd are obtained by well-established law.
As the form with the food of antitumor action of the present invention, except tea, as long as nourishing drink, jelly, biscuit, tablet, pill, soft capsule, hard capsule, powder, granula subtilis, granule etc., usually used as the available form of food, can use any form.As auxiliary material, also the additives such as excipient, tackiness agent, lubricant, dispersion agent, suspension agent, emulsifying agent, thinner, buffer reagent, antioxidant, bacterial inhibitor can be used.
The present invention has effective intake of each novel cpd of the food of antitumor action, different according to the difference at picked-up form, the state of health of object, the age of object etc., but being generally every day is for each person 0.001 ~ 100mg, be preferably 0.01 ~ 10mg, more preferably 0.1 ~ 1mg.
The present invention has the content of each novel cpd in the food of antitumor action, different according to the difference of food form, but is generally 0.0001 ~ 1wt%, is preferably 0.001 ~ 0.5wt%, is more preferably 0.01 ~ 0.1wt%.
As the example of the form of external application pharmaceuticals of the present invention and makeup, be not particularly limited.
As the form of external application pharmaceuticals, such as, can exemplify ointment, creme, paste, adhesive tape agent, external preparation etc.Pharmaceuticals of the present invention, on the basis of each novel cpd, can contain other medical components as required, in addition, also can use the additives such as tackiness agent, dispersion agent, suspension agent, emulsifying agent, thinner, buffer reagent, antioxidant, bacterial inhibitor.
As the form of makeup, astringent, beauty liquid, emulsion, breast frost, gel, facial mask, beauty treatment muffin, cleansing milk, baths etc. can be used as the spendable any form of external preparation cosmetic formulations.In above-mentioned makeup, on the basis of the required compositions such as the partial purification product of the sterling of each novel cpd, this novel cpd, the crude extract of this novel cpd extracted from plant or the plant materials containing this novel cpd, also can as required containing the composition that can coordinate in cosmetic formulations.As gradation composition, such as, can exemplify solid oil, lard, liquid oils, low molecule wetting Agent for Printing Inks, polymer wetting Agent for Printing Inks, fat-soluble wetting Agent for Printing Inks, softener, tensio-active agent, sanitas, antioxidant, pH adjusting agent, ethanol, water etc.
Effective dosage of each novel cpd used time outside, according to the symptom of object, the difference at the age of object and different, but to be generally every day be for each person 0.001 ~ 100mg, is preferably 0.01 ~ 10mg, more preferably 0.1 ~ 1mg.
The content of each novel cpd in antineoplastic agent of the present invention, pharmaceuticals, makeup, separately or be generally 0.0001 ~ 1wt% as during mixture, is preferably 0.001 ~ 0.5wt%, is more preferably 0.01 ~ 0.1wt%.
Embodiment
Below by embodiment, the invention will be further described.The method described in the embodiment of the present invention that it should be understood that is only used for the present invention is described, instead of limitation of the present invention, under concept thereof of the present invention, all belong to the scope of protection of present invention to the simple modifications of preparation method of the present invention.The all raw materials used in embodiment and solvent are all purchased from Sigma Biochemical and Organic Compounds for Research and Diagnostic Clinical Reagents company.
Embodiment 1: the preparation of formula I
At room temperature, with 90% (v/v) ethanol of 25L, the extraction that each 24 hours amount to 3 times is carried out to manioca dry root (5Kg), concentrate after these are combined, obtain dry substance (407g).Then, after making its dissolving that suspends in 90% (v/v) methyl alcohol of 7L, carry out 3 sub-distribution with the hexane of equivalent, then take out 90% (v/v) methanol phase and carry out concentrating under reduced pressure.In this concentrating under reduced pressure thing, add pure water to 5L, move in separating funnel and carry out 3 two-phase solvents distribution with chloroform.Then the chloroform obtained by this operation is combined mutually, obtain dry substance 69.3g.By wherein 69.0g supply using the silica gel column chromatography (80mm φ × 150mm, Kanto Kagaku K. K. system) of hexane/ethyl acetate as eluting solvent.That is: after successively silicagel column being washed by the eluting solvent hexane/ethyl acetate (7: 3) of the eluting solvent hexane/ethyl acetate (9: 1) of 3 bed volumes (BV), the eluting solvent hexane/ethyl acetate (8: 2) of 2BV and 2BV, use eluting solvent hexane/ethyl acetate (6: the 4) wash-out of 2BV again, obtain component C (dry substance 3.73g).Then, for component C, implement the Sephadex LH-20 column chromatography (20mm φ × 200mm, Pharmacia Inc.) of methyl alcohol as eluting solvent.That is:, after being washed by post with the methyl alcohol of 2BV, by the methanol-eluted fractions of 1BV, component F (dry substance 369mg) is obtained.Then, component F (dry substance 369mg) is supplied the Flash ODS column chromatography (20mm φ × 150mm, wild village chemical company system) of water/methyl alcohol as eluting solvent.That is: after Flash ODS post being washed with 50% (v/v) methyl alcohol of 180ml, after using 60% (v/v) methyl alcohol, 70% (v/v) methanol wash step by step successively, by 80% (v/v) methanol-eluted fractions, obtain the component G (dry substance 75.6mg) containing target novel cpd A.And then, with preparative high performance liquid chromatography (ODS post, 20mm φ × 250mm, chemical company of wild village system, moving phase: 45% (v/v) acetonitrile, detection: 254nm UV detector), purifying is carried out to component G (dry substance 75.6mg), obtain novel cpd A (dry substance 9.8mg).In addition, in above-mentioned, high performance liquid chromatography employs Waters 515 system and Waters 600 system (being Japanese Waters Co., Ltd. system).In addition, silica gel column chromatography, Sephadex LH-20 column chromatography and Flash ODS chromatography use usual experimental apparatus and experimental installation.
The structural analysis of formula I A use nuclear magnetic resonance spectrometry (
1h NMR) carry out.Below represent result.
1H NMR(CDCl
3，500MHz)：δ3.69(H-14，J＝11.2Hz，1H，d)、3.75(H-14，J＝11.2Hz，1H，d)、3.95(8，3H，s)、4.22(H-2，J＝11.7Hz，1H，d)、4.31(H-2，J＝11.7Hz，1H，d)、5.93(H-4，J＝11.7Hz，1H，d)、6.43(H-5，J＝11.7Hz，1H，d)、6.51(H-7，1H，s)、7.47(H-10，J＝1.5，6.7，7.5Hz，1H，m)、7.50(H-11，J＝1.5，6.7，7.5Hz，1H，m)、8.14(H-9，J＝1.5，7.5Hz，1H，d)、8.24(H-12，J＝1.5，7.5Hz，1H，d).
Embodiment 2: anti-tumor activity is tested
Study on antitumor effect is undertaken by the proliferation inhibition activity measured for the melanoma cell strain HMV-II from human body.
Use the Ham F12 substratum containing 10% (v/v) foetal calf serum, with 1 × 10 on 96 hole culture plates (NUNC)
4the cell concn inoculation of cells/90 μ l from the melanoma cell strain HMV-II of human body, 37 DEG C, under 5% carbon dioxide exists, carry out cultivating for 24 hours.Cultivate after 24 hours, adding formula I of the present invention (is dissolved in DMSO, final DMSO concentration=0.1% (v/v) in substratum, in addition, by cultured cells strain on the substratum of DMSO only adding 1/1000 volume as a control group), so 37 DEG C, 5% carbon dioxide exist under cultivate 24 hours.The mensuration of relative growth rate uses tetrazolium bromide (MTT) [3-(4,5-dimethylthiazole-2-base)-2,5-phenylbenzene bromination tetrazole Nacalai Tesque] [(3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazol ium bromide)] method carry out [with reference to Co., Ltd. Tokyo chemistry with people's distribution, new biochemical experiment lecture 12 molecular immunology I immune cells factor 358-359 page].That is: add after above-mentioned each novel cpd cultivates 24 hours, at 96 hole culture plate (0.33cm
2/ well) each hole nutrient solution 90 μ l in add the MTT solution { 5mg/ml of 10 μ l; After dissolving in without calcium magnesium PBS [Du Shi phosphoric acid buffer (Dulbecco ' s Phosphate-Buffered Saline)] solution, solution after film filter (0.22 μm) filters }, carrying out vibration makes it even, 37 DEG C, 5% carbon dioxide cultivates 4 hours under existing.Cultivate after 4 hours in each hole, add 10% (w/v) SDS-50% (v/v) N, dinethylformamide-0.005N hydrochloric acid soln 100 μ l, 37 DEG C, 5% carbon dioxide leaves standstill after 18 hours under existing, use immune detector (immuno reader) (Dainippon Pharmaceutical Co., Ltd's system), with 750nm in contrast, measure the absorbancy at 590nm place, as the index of relative growth rate.Formula I of the present invention is under the concentration of 10 μ g/ml, and appreciation rate is 85%.The excellent proliferation inhibition activity of formula I to the melanoma cell strain (HMV-II) from human body can be confirmed.
Claims (3)
1. a compound, is characterized in that it is with shown in following structural formula:
I。
2. an antineoplastic composition, is characterized in that containing the compound shown in formula I and pharmaceutically acceptable auxiliary agent.
3. a protective foods, is characterized in that containing the compound shown in formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410707859.6A CN104447674A (en) | 2014-12-01 | 2014-12-01 | Compound used as antitumor drug and food |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410707859.6A CN104447674A (en) | 2014-12-01 | 2014-12-01 | Compound used as antitumor drug and food |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104447674A true CN104447674A (en) | 2015-03-25 |
Family
ID=52894499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410707859.6A Pending CN104447674A (en) | 2014-12-01 | 2014-12-01 | Compound used as antitumor drug and food |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104447674A (en) |
-
2014
- 2014-12-01 CN CN201410707859.6A patent/CN104447674A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10898535B2 (en) | Composition for inhibiting and preventing myopathy, containing bean leaf extract as active ingredient | |
| TWI648257B (en) | Compounds from antrodia camphorata, method for preparing the same and use thereof | |
| CN102160862B (en) | Antiobesity agent and pharmaceutical, food, or cosmetic provided with fat accumulation inhibiting effect | |
| CN104189086A (en) | Preparation method and new application of lupulus natural pharmaceutical composition | |
| JP4836961B2 (en) | Expression inhibitor of nuclear transcription factor AP-1, pharmaceutical and product using the same | |
| CN103467293B (en) | Novel compound and application thereof in pharmaceuticals, food or cosmetics with anti-tumor function | |
| TW201540320A (en) | Ceramide production enhancer and moisturizing agent | |
| WO2013015519A1 (en) | Antioxidant composition containing isorhamnetin-3-glucoside-7-rhamnoside separated from hippophae rhamnoides leaves as an active ingredient | |
| CN102838464B (en) | New compound selaginellin N with anticancer activity, and uses thereof | |
| CN102475698A (en) | Application of salvianolic acid L in preparation of medicines used for treating tumor | |
| CN102133220A (en) | Preparation method of pulsatilla saponin matter as well as preparation method of preparation thereof and application of pulsatilla saponin matter in preparing medicaments for treating cancers | |
| TW201705970A (en) | Nerve cell death inhibitor, anti-alzheimer's disease agent, brain hypofunction inhibitor, drug or food having anti-alzheimer's disease effect or brain hypofunction-inhibiting effect, and method for producing nerve cell death inhibitor | |
| CN102838465B (en) | New compound selaginellin M with anticancer activity, and uses thereof | |
| JP2005023000A (en) | Anti-bacterial agent and method for producing the same, and food preparation and antiseptic | |
| CN104447674A (en) | Compound used as antitumor drug and food | |
| CN104447335A (en) | Compound used as antitumor drug or food | |
| CN104447266A (en) | Compound used as antitumor drug and food | |
| JP2011195489A (en) | Scirpusin b-containing composition and method for producing the same | |
| CN105218495A (en) | A kind of red sage root water soluble ingredient new compound, preparation method and application thereof | |
| JP6688585B2 (en) | Barrier function improver | |
| CN109867657B (en) | Dihydroxydibenzo [ b, f ] [1,5] dioxacin ring compound, preparation method, pharmaceutical composition and application thereof | |
| JP7393457B2 (en) | Furan aspidospermine dimer or its pharmaceutically acceptable salt, its production method and application, and pharmaceutical composition | |
| KR100641968B1 (en) | Physiologically active extract | |
| CN117682988A (en) | Wangzaozi B derivative, and preparation method and application thereof | |
| JP2021187799A (en) | Lymphatic endothelial cell migration promoter |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150325 |
|
| WD01 | Invention patent application deemed withdrawn after publication |